Madrigal Pharma (MDGL) option IV into FDA approves Madrigal Pharmaceuticals' Rezdiffra
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Join SI Premium – FREE
Madrigal Pharma (NASDAQ: MDGL) 30-day option implied volatility is at 151; compared to its 52-week range of 49 to 176 into FDA approves Madrigal Pharmaceuticals' Rezdiffra.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi initiates Madrigal Pharmaceuticals coverage with Buy rating
- Meta Platforms (META) call put ratio 1.7 calls to 1 put with a focus on 11200 contracts of October 16 calls trading at $60
- Southwest Airlines (LUV) 26K contracts of September 44 calls trade
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
